| Not Yet Recruiting | Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas Aggressive B-cell Lymphomas | — | 2026-05-01 |
| Recruiting | Glofitamab in Real Life Large B-cell Lymphoma | — | 2025-12-01 |
| Recruiting | Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rit Primary CNS Lymphoma (PCNSL) | Phase 2 | 2025-09-22 |
| Recruiting | A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas Peripheral T Cells Lymphoma (PTCL) | Phase 1 / Phase 2 | 2025-08-20 |
| Recruiting | Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma Lymphoma, Mantle-Cell | Phase 2 | 2025-02-21 |
| Completed | FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow DLBCL - Diffuse Large B Cell Lymphoma | — | 2024-09-30 |
| Recruiting | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma | Phase 2 | 2024-06-14 |
| Recruiting | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma Follicular Lymphoma | Phase 3 | 2024-06-07 |
| Recruiting | Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone L Marginal Zone Lymphoma | Phase 3 | 2023-09-05 |
| Completed | Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) Follicular Lymphoma | — | 2022-11-07 |
| Active Not Recruiting | Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma Mantle Cell Lymphoma | Phase 2 | 2022-01-24 |
| Active Not Recruiting | Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patie DLBCL | Phase 2 | 2021-12-20 |
| Recruiting | Study of Lacutamab in Peripheral T-cell Lymphoma Peripheral T Cell Lymphoma, Relapse/Recurrence | Phase 2 | 2021-10-05 |
| Active Not Recruiting | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma Lymphoma, B-Cell | Phase 2 | 2021-06-11 |
| Completed | Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma | Phase 2 | 2021-03-30 |
| Active Not Recruiting | Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autolog B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Phase 2 | 2021-03-10 |
| Recruiting | French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T) Hematopathology Eligible or CAR-t Cell Treatment | — | 2019-12-19 |
| Terminated | Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 | 2019-07-04 |
| Completed | Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Aggressive Non-Hodgkin Lymphoma | Phase 2 | 2018-12-26 |
| Active Not Recruiting | Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma | Phase 3 | 2018-11-09 |
| Completed | Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma Hodgkin Lymphoma, Coexisting Medical Conditions | Phase 2 | 2018-08-31 |
| Completed | Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma Anaplastic Large Cell Lymphoma, ALK-Positive | — | 2018-08-02 |
| Completed | Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 2 | 2018-04-10 |
| Completed | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma | Phase 2 | 2018-02-12 |
| Terminated | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy DLBCL | Phase 1 / Phase 2 | 2017-07-26 |
| Recruiting | Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) | — | 2017-06-07 |
| Completed | Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL) Diffuse Large B Cell Lymphoma | — | 2017-05-09 |
| Completed | Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Mainte Mantle Cell Lymphoma | Phase 2 | 2016-11-29 |
| Completed | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAO B-cell Lymphoma | Phase 1 | 2016-10-01 |
| Active Not Recruiting | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chem Lymphoma, DLBCL, Follicular Lymphoma | Phase 1 / Phase 2 | 2016-10-01 |
| Completed | Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE Hodgkin Disease | Phase 1 / Phase 2 | 2016-03-01 |
| Completed | Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lym Primary Central Nervous Lymphoma, Intraocular Lymphoma | Phase 2 | 2015-09-01 |
| Completed | Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxor Classical Hodgkin Lymphoma | Phase 2 | 2015-07-17 |
| Completed | Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycle Hodgkin Lymphoma | Phase 2 | 2015-04-01 |
| Completed | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. Hodgkin Lymphoma | Phase 2 | 2015-03-01 |
| Completed | Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) Follicular Lymphoma | Phase 3 | 2015-02-02 |
| Completed | Detection and Characterization of Residual Masses in Lymphomas Hodgkin Lymphoma, B-Cell Lymphoma | — | 2014-10-01 |
| Completed | Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ Diffuse Large B Cell Lymphoma | Phase 3 | 2014-08-01 |
| Terminated | Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas B-cell Lymphoma | Phase 1 | 2014-05-26 |
| Completed | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With Mantle Cell Lymphoma | Phase 3 | 2013-11-01 |
| Completed | A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgk Hodgkin's Lymphoma | Phase 2 | 2013-07-04 |
| Terminated | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Le Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma, Primary Central Nervous System Lymphoma | Phase 2 | 2013-02-01 |
| Completed | A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-C Relapsed/Refractory B-cell Lymphoma | Phase 1 | 2013-02-01 |
| Completed | Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Peripheral T-cell Lymphoma | Phase 3 | 2013-01-01 |
| Completed | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lympho Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | 2012-12-01 |
| Completed | Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggress Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) | Phase 1 / Phase 2 | 2012-10-03 |
| Terminated | GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma CD20 Positive | Phase 3 | 2012-09-01 |
| Completed | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-50 Follicular Lymphoma | Phase 3 | 2012-02-01 |
| Completed | The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas Non-Hodgkin's Lymphomas | Phase 1 | 2011-12-01 |
| Completed | Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) T-cell Lymphoma | Phase 2 | 2011-11-01 |
| Completed | Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patie Mantle Cell Lymphoma Refractory | Phase 1 / Phase 2 | 2011-11-01 |
| Terminated | BRIEF Bendamustine and Rituximab In Elderly Follicular Follicular Lymphoma | Phase 2 | 2011-02-01 |
| Completed | A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymph Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | 2011-01-01 |
| Completed | Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ P DLBCL | Phase 3 | 2010-12-01 |
| Completed | Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma Follicular Lymphoma | Phase 2 | 2010-12-01 |
| Completed | Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Year Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma | Phase 2 | 2010-05-01 |
| Completed | Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R- Lymphoma, Diffuse Large B-cell Lymphoma | Phase 3 | 2009-04-01 |